Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PHLDB2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PHLDB2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PHLDB2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PHLDB2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PHLDB2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PHLDB2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PHLDB2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004804122 | Lung | AAH | focal adhesion assembly | 12/613 | 87/18723 | 2.57e-05 | 3.42e-03 | 12 |
GO:005189322 | Lung | AAH | regulation of focal adhesion assembly | 10/613 | 66/18723 | 5.32e-05 | 5.35e-03 | 10 |
GO:009010922 | Lung | AAH | regulation of cell-substrate junction assembly | 10/613 | 66/18723 | 5.32e-05 | 5.35e-03 | 10 |
GO:003432922 | Lung | AAH | cell junction assembly | 30/613 | 420/18723 | 5.80e-05 | 5.52e-03 | 30 |
GO:005101723 | Lung | AAH | actin filament bundle assembly | 16/613 | 157/18723 | 5.91e-05 | 5.52e-03 | 16 |
GO:000704423 | Lung | AAH | cell-substrate junction assembly | 12/613 | 95/18723 | 6.24e-05 | 5.72e-03 | 12 |
GO:190290323 | Lung | AAH | regulation of supramolecular fiber organization | 28/613 | 383/18723 | 6.82e-05 | 6.09e-03 | 28 |
GO:006157223 | Lung | AAH | actin filament bundle organization | 16/613 | 161/18723 | 7.99e-05 | 6.21e-03 | 16 |
GO:000716022 | Lung | AAH | cell-matrix adhesion | 20/613 | 233/18723 | 8.74e-05 | 6.57e-03 | 20 |
GO:015011623 | Lung | AAH | regulation of cell-substrate junction organization | 10/613 | 71/18723 | 1.00e-04 | 7.08e-03 | 10 |
GO:015011523 | Lung | AAH | cell-substrate junction organization | 12/613 | 101/18723 | 1.14e-04 | 7.56e-03 | 12 |
GO:190188821 | Lung | AAH | regulation of cell junction assembly | 18/613 | 204/18723 | 1.37e-04 | 8.75e-03 | 18 |
GO:003158923 | Lung | AAH | cell-substrate adhesion | 26/613 | 363/18723 | 1.70e-04 | 1.03e-02 | 26 |
GO:003003823 | Lung | AAH | contractile actin filament bundle assembly | 12/613 | 106/18723 | 1.81e-04 | 1.05e-02 | 12 |
GO:004314923 | Lung | AAH | stress fiber assembly | 12/613 | 106/18723 | 1.81e-04 | 1.05e-02 | 12 |
GO:000195222 | Lung | AAH | regulation of cell-matrix adhesion | 13/613 | 128/18723 | 2.95e-04 | 1.45e-02 | 13 |
GO:003297023 | Lung | AAH | regulation of actin filament-based process | 27/613 | 397/18723 | 2.96e-04 | 1.45e-02 | 27 |
GO:003295623 | Lung | AAH | regulation of actin cytoskeleton organization | 25/613 | 358/18723 | 3.31e-04 | 1.55e-02 | 25 |
GO:001081023 | Lung | AAH | regulation of cell-substrate adhesion | 18/613 | 221/18723 | 3.70e-04 | 1.69e-02 | 18 |
GO:190290422 | Lung | AAH | negative regulation of supramolecular fiber organization | 15/613 | 167/18723 | 4.01e-04 | 1.78e-02 | 15 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PHLDB2 | SNV | Missense_Mutation | novel | c.1172N>T | p.Asp391Val | p.D391V | Q86SQ0 | protein_coding | deleterious(0) | benign(0.203) | TCGA-A7-A425-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | PD |
PHLDB2 | SNV | Missense_Mutation | novel | c.3502N>A | p.Asp1168Asn | p.D1168N | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.359N>A | p.Gly120Glu | p.G120E | Q86SQ0 | protein_coding | tolerated_low_confidence(0.09) | benign(0.018) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PHLDB2 | SNV | Missense_Mutation | | c.1708N>G | p.Ile570Val | p.I570V | Q86SQ0 | protein_coding | tolerated(0.1) | benign(0.255) | TCGA-B6-A0WV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.604C>T | p.Pro202Ser | p.P202S | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.549) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
PHLDB2 | SNV | Missense_Mutation | | c.1690N>C | p.Glu564Gln | p.E564Q | Q86SQ0 | protein_coding | deleterious(0.05) | benign(0.388) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.1608N>T | p.Arg536Ser | p.R536S | Q86SQ0 | protein_coding | tolerated(0.07) | benign(0.057) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
PHLDB2 | SNV | Missense_Mutation | | c.3134N>T | p.Ala1045Val | p.A1045V | Q86SQ0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PHLDB2 | SNV | Missense_Mutation | novel | c.7N>A | p.Glu3Lys | p.E3K | Q86SQ0 | protein_coding | deleterious_low_confidence(0) | benign(0.214) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PHLDB2 | SNV | Missense_Mutation | novel | c.3132N>T | p.Gln1044His | p.Q1044H | Q86SQ0 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD |